Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Acadia Healthcare Q2 revenue beats in inpatient growth but costs bite

Acadia Healthcare Q2 revenue beats in inpatient growth but costs bite

ReutersReuters2026/07/28 20:24
By:Reuters


Overview

  • US behavioral healthcare provider's Q2 revenue was flat yr/yr, beating analyst expectations

  • Adjusted EBITDA for Q2 slightly beat analyst consensus

  • Company added 240 licensed beds from newly constructed facilities in Q2


Outlook

  • Acadia Healthcare raises 2026 revenue guidance to $3.40-$3.45 bln from $3.37-$3.45 bln

  • Company lifts 2026 adjusted EBITDA forecast to $590-$615 mln from $580-$615 mln

  • Acadia Healthcare increases 2026 operating cash flow outlook to $350-$400 mln from $285-$325 mln


Result Drivers

  • SUPPLEMENTAL PAYMENT TIMING - Flat revenue and same-facility revenue were impacted by the timing of supplemental payment program revenue in Florida and Tennessee

  • HIGHER OPERATING COSTS - Adjusted EBITDA declined due to a $39.3 mln increase in professional and general liability costs, including a $28.6 mln reserve adjustment, and higher salaries and benefits

  • VOLUME GROWTH IN ACUTE INPATIENT - Acute inpatient volumes rose 5.5%, driven by expanded capacity from new and existing facilities


Company press release: ID:nBw86FNda


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$865.84 mln

$844.23 mln (10 Analysts)

Q2 Net Income

$12.26 mln

Q2 Adjusted EBITDA

Slight Beat*

$149.20 mln

$148.18 mln (11 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities services peer group is "buy"

  • Wall Street's median 12-month price target for Acadia Healthcare Company Inc is $31.50, about 3.1% below its July 27 closing price of $32.50

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • July 27 - Universal Health Services cuts 2026 forecast on Medicaid reimbursement uncertainty

  • July 28 - Centene flags weakening Medicaid membership, shares fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Adds Another Lululemon (LULU.US) Short Seller! After an 81% Plunge from its Peak, BMO Warns Tough Times Are Still Ahead

BMO Capital Markets believes that Lululemon’s turnaround from losses will not be swift or easy. The sportswear company is handing over market share to competitors, and the decline in sales continues to deepen.

智通财经2026/09/12 06:11
Wall Street Adds Another Lululemon (LULU.US) Short Seller! After an 81% Plunge from its Peak, BMO Warns Tough Times Are Still Ahead